Niagen Bioscience wins FDA rare pediatric disease designation for NB4168 in ataxia telangiectasia - NAGE News | RalliesNiagen Bioscience wins FDA rare pediatric disease designation for NB4168 in ataxia telangiectasia
N
NAGE• FDA and EMA designations for NB4168
- Niagen Bioscience won FDA Rare Pediatric Disease designation for NB4168 to treat ataxia-telangiectasia.
- EMA granted orphan medicinal product designation for NB4168, supporting global clinical development incentives for the rare genetic disorder.
